July 1, 2021 5:07pm

Yet, a profit-taking session with news from Mesoblast (MESO) with a pre-open of +$1.12 which only closed +$0.06 – oh, the strippage but, its till closed positive

Pre-open indications: 5 HITs and 2 MISS

My comments try to distinguish the temporary from real pricing digression or progress.

If you’re looking for sector intel, ideas and facts or numbers (which don’t lie) in a volatile climate, RMi defines the rigors of share pricing! My comments distinguish the temporary from real pricing digression or progress.

Subscription is coming in July, it’s not conscription but, an offer to join our collective of like-minded investors!  

The Dow closed UP +131.02 points (+0.38%); the S&P closed UP +22.44 points (+0.52%) while the Nasdaq closed UP +18.42 points (+0.13%)

 

Henry’omics:

Indexes were up on day 1 of Q3 and the 2nd half

For the year, the Dow is up 12.7%, hovering about 1.7% below its all-time high. The S&P 500 rallied 14.4% in the 1st half of 2021 and the Nasdaq rose 12.5%.

Interesting quote, "Historical data shows if you have a strong first half, the second half of the year was actually going even stronger," said Ross Mayfield, investment strategy analyst with Baird Private Wealth.

Also, “The ongoing worker shortage, attributed to federal emergency unemployment benefits, a childcare shortage and lingering pandemic fears, was a common theme in the day's economic data.”

 

Data Docket: weekly initial jobless claims came in at 364,000, setting a pandemic-era low. Economists were expecting initial claims for unemployment totaled 390,000 last week, after totaling 415,000 for the week ended June 19. Also, the Institute for Supply Management’s June manufacturing index showed an expansion that was roughly in line with expectations, and the Congressional Budget Office hiked its estimates for economic growth.

 

RegMed Investors’ (RMi) pre-open: “what a difference news makes” …  https://www.regmedinvestors.com/articles/11981

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Thursday opened positive at 19/11, 4 flats and 1 acquired stayed positive at the mid-day at 21/13, 3 flats and 1 acquired, closing positive at 25/8, 1 flat and 1 acquired;

 

The Biostage (BSTG) Chronicles: The “pump” is STILL promoting on Thursday with 408 shares “ “appearing” to boost the share price +$0.095 to $1.35 after Wednesday’s -$0.005 (was -$0.11) to $1.25 with 3,241 shares traded after Tuesday as 1,860 shares “appeared” as the share price was sinking -$0.07 to lift it +$0.03 after Monday’s 1,177 shares trading and the share price dripped -$0.02 to $1.23, Friday’s 1,600 shares traded as the stock dropped -$0.10 to $1.25 and last Thursday with 1,920 shares traded to “putt” the share price at $0.10 to $1.35 … WHO is buying this “zombie pig” as IF we didn’t know?  After yet another warrant execution and ever-increasing UN-REGIGISTERED share DILUTION and .. the potential THREAT is of de-listing if the share price was to trade without the “pump” below $1.00?

 

Pre-open Indications: 5 HITs < BUY: Mesoblast (MESO +$0.16); SELL into Strength: Ionis Pharmaceuticals (IONS +$0.16), Intellia Therapeutics (NTLA +$6.74), Editas Medicine (EDIT -$0.12); Maintaining BUY:  Global Blood Therapeutics (GBT +$2.32) and 2 MISS < Biostage (BSTG +$0.095); CRISPR Therapeutics (CRSP -$5.25);

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Intellia Therapeutics (NTLA) – another again plus two, Fate Therapeutics (FATE), ReNeuron (RENE.L), Global Blood therapeutics (GBT) – again, Cellectis SA (CLLS) to name 5 of the 25 inclining of the 35

Hammered in today’s market:

  • CRISPR Therapeutics (CRSP), Ultragenyx (RARE) – again, Editas Medicine (EDIT), Voyager Therapeutics (VYGR), Caladrius Biosciences (CLBS), Chinook therapeutics (KDNY), Brainstorm Cell Therapeutics (BCLI), Pluristem (PSTI) to name 8 of the 8 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 5 of the 25-upside having higher than the 3-month average volume with LOW volume of 3 of 8-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 25-upside were +0.14% (ALNY) to +8.64% (FATE) while the 8-downside ranges from -0.21% (EDIT) to -3.24% (CRSP);

 

Thursday’s (10 of 25) incliners:

  • Intellia therapeutics (NTLA +$9.74 after Wednesday’s +$10.30, Tuesday’s +$18.18 and Monday’s +$44.60);
  • Fate Therapeutics (FATE +$7.50 after Wednesday’s -$2.37, Tuesday’s +$0.04 and Monday’s +$4.57);
  • Global Blood Therapeutics (GBT +$2.32 after Wednesday’s +$2.56, Tuesday’s -$0.73 and Monday’s -$3.25);
  • ReNeuron (RENE.L +$2.00 after Wednesday’s +$1.50, Tuesday’s -$3.50 and Monday’s +$0.50);
  • Regenxbio (RGNX +$0.74 after Wednesday’s +$0.41, Tuesday’s -$0.54 and Monday’s -$1.50);
  • Cellectis SA (CLLS +$0.62);
  • Sage Therapeutics (SAGE +$0.56 after Wednesday’s +$0.43, Tuesday’s -$0.82 and Monday’s -$1.14);
  • uniQure NV (QURE +$0.46 after Wednesday’s -$0.39);
  • bluebird bio (BLUE +$0.44 after Wednesday’s +$1.90, Tuesday’s -$1.09);
  • MiMedx (MDXG +$0.41);

Thursday’s (8 of 8) decliners:

  • CRISPR Therapeutics (CRSP -$5.25 after Wednesday’s +$11.40, Tuesday’s -$1.14 and Monday’s +$9.11);
  • Ultragenyx (RARE -$1.24 after Wednesday’s -$0.94);
  • Editas Medicine (EDIT -$0.12 after Wednesday’s +$10.54, Tuesday’s +$2.11 and Monday’s +$2.11);
  • Voyager Therapeutics (VYGR -$0.05);
  • Caladrius Biosciences (CLBS -$0.04);
  • Chinook Therapeutics (KDNY -$0.03 after Wednesday’s -$0.12, Tuesday’s -$0.97 and Monday’s -$0.38);
  • Brainstorm cell Therapeutics (BCLI -$0.01);
  • Pluristem (PSTI -$0.01);

Closing 1 – Verastem (VSTM) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed up +0.89% and XBI closed up +2.28%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was down -0.35 points or -2.21% at 15.48

Upside volume: weak

  • Thursday: 5 out of the 25-upside had higher than the 3-month average volume;

Downside volume:

  • Thursday: 3 out of the 8-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Thursday’s percentage (%) of the 25-upside were +0.14% (ALNY) to +8.64% (FATE) while the 8-downside ranges from -0.21% (EDIT) to -3.24% (CRSP);

 

July, first month of Q3/21:

Thursday (7/1) closed positive with 25 advancers, 8 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: As I had stated, “It's end of the quarter and investors may want to take some profits and rotate out of some stem, cell and gene therapy sector equities, which has seen some multiple session highs.”

Don’t forget there is a long holiday weekend coming (and my birthday) – many will bolt and possibly equities as well?

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

July starts on a positive note, and be careful of a long, hot, volatile summer.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.